Lung Cancer
RSSArticles
-
Lessons in Supportive Care, IX: Preventing the Death of Hospice
-
Did You Know?
-
Paclitaxel Hypersensitivity: It's the Vehicle That Gets You There
-
New Hope for Immunologic Approaches to Metastatic Melanoma
-
Lowering the Threshold for Prophylactic Platelet Transfusion: Is the Risk of
-
Concomitant and Subsequent Chemotherapy Enhances Responses to Advanced Nasophary
-
Systemic Radiation Therapy Using Receptor Specific Radioligands: Experience with
-
Cancer Screening's Next Chapter: Mobile CT Scanning for Lung Cancer
-
Lessons in Supportive Care, IX: Do Medical Care Interventions Ever Save Money?
-
Strategy to Overcome Rituximab Resistance in Patients with Indolent Lymphoma
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles).